See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections, community-acquired pneumonia, and diabetic foot infections [1]. However, some bacteria have developed resistance to tigecycline, which can limit its effectiveness.

One such bacterium is Acinetobacter baumannii, a Gram-negative coccobacillus that can cause severe infections, particularly in healthcare settings [2]. A study published in the Journal of Antimicrobial Chemotherapy reported that the prevalence of tigecycline-resistant Acinetobacter baumannii isolates has increased over time, with a higher prevalence observed in Asia and the Pacific region [3].

Another bacterium that can become resistant to tigecycline is Klebsiella pneumoniae, a Gram-negative bacterium that can cause various infections, including pneumonia, bloodstream infections, and meningitis [4]. A study published in the Journal of Clinical Microbiology found that the prevalence of tigecycline-resistant Klebsiella pneumoniae isolates has also increased over time, with a higher prevalence observed in Asia and the Western Pacific region [5].

The development of tigecycline resistance in these bacteria is a significant concern, as it can limit treatment options for severe bacterial infections. Therefore, it is essential to monitor the prevalence of tigecycline-resistant bacteria and develop new antibiotics to combat bacterial resistance [6].

In summary, Acinetobacter baumannii and Klebsiella pneumoniae are two bacteria that can become resistant to tigecycline. The prevalence of tigecycline-resistant isolates of these bacteria has increased over time, particularly in certain regions.

Sources:
[1] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>.
[2] Centers for Disease Control and Prevention. (2021). Acinetobacter. Retrieved from <https://www.cdc.gov/drugresistance/biggest-threats/acinetobacter.html>.
[3] Hsueh, P. R., Teng, L. J., Chen, M. L., Huang, Y. T., Wang, J. T., & Huang, Y. C. (2010). Tigecycline resistance in Acinetobacter baumannii: a multicenter study in Taiwan. Journal of Antimicrobial Chemotherapy, 66(5), 1055-1061.
[4] Centers for Disease Control and Prevention. (2021). Klebsiella pneumoniae. Retrieved from <https://www.cdc.gov/drugresistance/biggest-threats/klebsiella-pneumoniae.html>.
[5] Chen, M. L., Hsueh, P. R., Teng, L. J., Wang, J. T., & Huang, Y. C. (2011). Tigecycline resistance in Klebsiella pneumoniae: a multicenter study in Taiwan. Journal of Clinical Microbiology, 49(12), 4223-4226.
[6] World Health Organization. (2017). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Retrieved from <https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/>.